Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Cancer (Impact Factor: 5.2). 02/2012; 118(4):981-6. DOI: 10.1002/cncr.26375
Source: PubMed

ABSTRACT Refractory germ cell tumor (GCT) patients have a poor prognosis and limited treatment options. The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents.
The characteristics and outcome of refractory GCT patients enrolled in 7 single-agent phase 2 trials conducted at Memorial Sloan-Kettering Cancer Center from 1990 to 2008 were reviewed. The study agents were suramin, all-transretinoic acid, topotecan, pyrazoloacridine, temozolomide, ixabepilone, and sunitinib. The major endpoints evaluated were response, progression-free survival (PFS), and overall survival (OS).
Ninety patients (87 male, 3 female) were treated. The primary tumor site was testis in 65 patients, mediastinum in 17 patients, retroperitoneum in 4 patients, and other in 4 patients. Eighty-six patients had nonseminoma, and 4 patients had pure seminoma. Best responses were 1 (1%) partial response (ixabepilone), 15 (17%) stable disease, and 74 (82%) progressive disease. Median PFS and OS were 1.0 month (95% confidence interval [CI], 0.8-1.3) and 4.7 months (95% CI, 3.5-6.4), respectively. Eighty-six of the 90 patients have died. The 12- and 16-week PFS rates were 9% (95% CI, 3-15%) and 6% (95% CI, 1%-11%), respectively.
Patients with refractory GCT progressed rapidly to these single agents. PFS and OS may be useful endpoints for designing phase 2 trials testing novel agents in this population. Twelve-week PFS (with comparison to the 9% benchmark rate reported herein) is the recommended endpoint for phase 2 trial design and median OS (using 4.7 months as the predicted median for the control arm) is suggested for phase 3 trials.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Testicular germ cell tumors (TGCTs) are the most common solid tumors in young adult men characterized by distinct biologic features and clinical behavior. Both genetic predispositions and environmental factors probably play a substantial role in their etiology. TGTCs arise from a malignant transformation of primordial germ cells in a process that starts prenatally, is often associated with a certain degree of gonadal dysgenesis, and involves the acquirement of several specific aberrations, including activation of SCF-CKIT, amplification of 12p with up-regulation of stem cell genes, and subsequent genetic and epigenetic alterations. Their embryonic and germ origin determines the unique sensitivity of TGCTs to platinum-based chemotherapy. Contrary to the vast majority of other malignancies, no molecular prognostic/predictive factors nor targeted therapy is available for patients with these tumors. This review summarizes the principal molecular characteristics of TGCTs that could represent a potential basis for development of novel diagnostic and treatment approaches.
    Critical reviews in oncology/hematology 10/2013; DOI:10.1016/j.critrevonc.2013.10.001 · 5.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE:: CD30 is expressed by untreated embryonal carcinoma (ECA) thus lending support to a rationale for a targeted approach. However, authors reported a chemotherapy-induced switch-off of CD30 at immunohistochemistry that might affect the therapeutic potential in relapsing disease. We aimed at evaluating the persistence of CD30-expression and its prognostic meaning in post-chemotherapy residuals. MATERIALS AND METHODS:: Paraffin blocks of surgical samples yielding non-teratoma viable cells after = 1 cisplatin-based chemotherapy were retrieved and re-assessed by two pathologists blinded to study purpose. Multivariable analyses (MVA) for pre-specified factors were undertaken. RESULTS:: From August 1991 to August 2012, a total of 49 cases of pure ECA or mixed germ-cell tumor had full clinical data and suitable tissue for analyses. Thirty-five cases (71.4%; 95% CI: 56.7-83.4%) preserved CD30 positivity. Of them, 14 (40.0%) had residual disease after after multiple regimens (median 1, IQR 1-2). Five-year overall survival of CD30-positive and negative patients was 37.0% (22.1-61.8%) and 50.1% (27.9-90.0%), respectively (p=0.078) while it was 23.2% (8.6-62.5%) and 47.6% (18.8-100%, p=0.025) beyond first-line. At MVA, CD30-positivity was a significant prognostic factor for progression-free (HR: 2.32; 95% CI: 1.04-5.19) and overall survival (HR: 2.77; 95% CI: 1.05-7.29). CONCLUSIONS:: CD30 was retained even after an intensive pre-treatment load, thus confirming to be a reliable target for treatment. Its expression associated with a significant poorer prognosis in multi-relapsed/chemoresistant cases and it was an independent prognostic factor for survival.
    The Journal of urology 04/2013; 190(5). DOI:10.1016/j.juro.2013.04.057 · 3.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose-Cryptogenic stroke is common in patients with cancer. Autopsy studies suggest that many of these cases may be because of marantic endocarditis, which is closely linked to cancer activity. We, therefore, hypothesized that among patients with cancer and ischemic stroke, those with cryptogenic stroke would have shorter survival. Methods-We retrospectively analyzed all adult patients with active systemic cancer diagnosed with acute ischemic stroke at a tertiary care cancer center from 2005 through 2009. Two neurologists determined stroke mechanisms by consensus. Patients were diagnosed with cryptogenic stroke if no specific mechanism could be determined. The diagnosis of marantic endocarditis was restricted to patients with cardiac vegetations on echocardiography or autopsy and negative blood cultures. Patients were followed until July 31, 2012, for the primary outcome of death. Kaplan-Meier statistics and the log-rank test were used to compare survival between patients with cryptogenic stroke and patients with known stroke mechanisms. Multivariate Cox proportional hazard analysis evaluated the association between cryptogenic stroke and death after adjusting for potential confounders. Results-Among 263 patients with cancer and ischemic stroke, 133 (51%) were cryptogenic. Median survival in patients with cryptogenic stroke was 55 days (interquartile range, 21-240) versus 147 days (interquartile range, 33-735) in patients with known stroke mechanisms (P<0.01). Cryptogenic stroke was independently associated with death (hazard ratio, 1.64; 95% confidence interval, 1.25-2.14) after adjusting for age, systemic metastases, adenocarcinoma histology, and functional status. Conclusions-Cryptogenic stroke is independently associated with reduced survival in patients with active cancer and ischemic stroke.
    Stroke 07/2014; 45(8). DOI:10.1161/STROKEAHA.114.005784 · 6.02 Impact Factor